EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Immunotherapy and Chemotherapy for Advanced or Recurrent Endometrial Carcinoma

John P Micha, Randy D Bohart, Joshua P Gorman, Bram H Goldstein

Anticancer Research · 2025

DOI: 10.21873/anticanres.17641 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Anticancer Research, 2025. Verfasst von John P Micha und 3 weiteren Autor:innen. Beteiligte Einrichtung: Women's Cancer Research Foundation, Laguna Beach, CA, U.S.A. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Neoplasm Recurrence, Local, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with early-stage endometrial cancer are frequently treated with surgery and radiotherapy or chemotherapy, for which 5-year survival rates approach 95%; conversely, the outcomes for patients with advanced or recurrent endometrial cancer are more inauspicious. Fortunately, the advent of immunotherapy, combined with chemotherapy, has conferred improved survival, especially in endometrial cancer patients with a mismatch repair deficiency (dMMR). We conducted an extensive PubMed search on the topics of endometrial cancer and immunotherapy treatment. The combination of dostarlimab and chemotherapy reportedly coincides with a 2-year progression-free survival (PFS) of 61% compared to a 12-month PFS of 74% for pembrolizumab. Moreover, the follow-up data for dostarlimab extended beyond 44 months and the median overall survival (OS) has not been reached compared to more limited OS data for both pembrolizumab and durvalumab; additionally, dostarlimab's pronounced risk of disease progression or death in both dMMR (70%) and mismatch repair-proficient (pMMR) (46%) patients is considerable. While pembrolizumab, dostarlimab and durvalumab with chemotherapy are associated with beneficial outcomes in advanced-stage or recurrent endometrial cancer, dostarlimab has distinguished itself with unsurpassed survival data compared to pembrolizumab and durvalumab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsNeoplasm Recurrence, LocalAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsImmune Checkpoint InhibitorsNeoplasm StagingSurvival RateDNA Mismatch RepairProgression-Free SurvivalHumansFemaleImmunotherapyAntibodies, MonoclonalAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

Endometrial cancerchemotherapyimmunotherapymismatch repair statusoutcomesreviewtolerability

Substanzen

dostarlimabAntineoplastic Agents, ImmunologicalpembrolizumabImmune Checkpoint InhibitorsdurvalumabAntibodies, MonoclonalAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Women's Cancer Research Foundation, Laguna Beach, CA, U.S.A.
  • Oso Home Care, Inc., Irvine, CA, U.S.A.
  • Department of Health Sciences, University of Arizona College of Medicine, University of Arizona, Tucson, AZ, U.S.A.
  • Women's Cancer Research Foundation, Laguna Beach, CA, U.S.A. bram@womenscancerfoundation.com.

Zitieren

APA

Micha, J. P., Bohart, R. D., Gorman, J. P., & Goldstein, B. H. (2025). Immunotherapy and Chemotherapy for Advanced or Recurrent Endometrial Carcinoma. Anticancer Research. https://doi.org/10.21873/anticanres.17641

Vancouver

Micha JP, Bohart RD, Gorman JP, Goldstein BH. Immunotherapy and Chemotherapy for Advanced or Recurrent Endometrial Carcinoma. Anticancer Research. 2025. doi:10.21873/anticanres.17641

BibTeX
@article{Micha2025,
  author = {Micha, John P and Bohart, Randy D and Gorman, Joshua P and Goldstein, Bram H},
  title = {Immunotherapy and Chemotherapy for Advanced or Recurrent Endometrial Carcinoma},
  journal = {Anticancer Research},
  year = {2025},
  doi = {10.21873/anticanres.17641}
}
Kostenlos starten →